• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Notice of Interim Results

by chantal | Jan 23, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell’s Modi-1 Moditope Vaccine Achieves Early Clinical Validation in Head and Neck Cancer

by chantal | Jan 9, 2025 | Latest News, Modi-1, Moditope, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell announces Genmab exercises option to a second commercial license agreement

by alex | Dec 4, 2024 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell announces further positive data from the ongoing SCOPE trial of SCIB1 with double CPIs for Advanced Melanoma

by chantal | Nov 18, 2024 | Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Result of 2024 Annual General Meeting

by admin | Oct 25, 2024 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell announces strengthening of leadership team as it closes on value-generating inflection points

by admin | Oct 22, 2024 | Latest News, News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Scancell Receives FDA Fast Track Designation for iSCIB1+
  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy